01 February 2023>: Lab/In Vitro Research
Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
Marcin Warpechowski 1CD* , Jędrzej Warpechowski 2AEF , Anita Pieńkowska 2BEF , Szymon Sagała 2BEF , Robert Milewski 1CDEDOI: 10.12659/MSM.938827
Med Sci Monit 2023; 29:e938827
Table 1 General characteristics of the study group of ulcerative colitis patients treated with Infliximab or Vedolizumab. (Word 2016, Microsoft Office).
All patients | |
---|---|
Number of patients | 35 |
Gender: male/female | 27/8 |
Age at diagnosis, median (interquartile range) | 28 (18–36) years |
Age at start of therapy, median (interquartile range) | |
Vedolizumab | 23 (18–31) years |
Infliximab | 32 (21–38) years |
Disease duration, median (interquartile range) | 7 (4–10) years |
UC location: proctitis/left-sided/pancolitis | 2/15/18 |
Contaminant therapies, n% | |
Immunomodulators | 9 (25.7%) |
Corticosteroids | 6 (17.14%) |
Mesalamine | 21 (60%) |
Sulfasalazine | 2 (5.7%) |
Partial Mayo score, median (interquartile range) | 7 (6–8) |
WBC (/μl), median (interquartile range) | 7950 (6025–9380) |
Platelet (×10/μl), median (interquartile range) | 257 (221–301) |
Neutrophils (×10/μl), median (interquartile range) | 4.718 (3.217–5.55) |
Hemoglobin (g/dl), median (interquartile range) | 13.25 (11.7–14.8) |
CRP (mg/l), median (interquartile range) | 2.75 (1.2–6.4) |
MPV (fl), median (interquartile range) | 9.9 (9.3–10.8) |
Neutrophil-to-platelet ratio, median (interquartile range) | 17.98 (14.16–21.40) |
UC – ulcerative colitis, WBC – white blood cells, CRP – C-reactive protein, MPV – mean platelet volume, μl – microliters, g/dl – grams per deciliter, mg/l – milligrams per liter, fl – femtoliters. |